Literature DB >> 7039820

Inhibition of cellular division of a murine macrophage tumor by macrophage-activating agents.

J E Talmadge, P A Donovan, I R Hart.   

Abstract

Although the murine reticulum cell sarcoma M5076 is highly malignant in vivo, in vitro it displays many of the functional characteristics of an activated macrophage, such as phagocytosis and tumor cytotoxicity. This study was designed to determine what effect macrophage-activating agents would have on the function and growth of M5076 cells. Exposure of M5076 tumor cells to substances that activate normal macrophages to the tumoricidal state rapidly and irreversibly induced cessation of cellular division. The treated tumor cells, however, retained the same characteristics as those of untreated M5076 cells in vitro with respect to viability and the activated macrophage functions of phagocytosis and tumor cytotoxicity. Even after a short exposure to lipopolysaccharide, the ability of M5076 cells, injected i.v. into syngeneic mice, to form tumor nodules was greatly reduced. These results indicate that a highly malignant tumor of macrophage origin, M5076, can be induced to cease cellular division while retaining the functional attributes of an activated macrophage. We speculate that the exposure of M5076 to macrophage-activating agents results in the induction of terminal differentiation of this tumor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039820

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.

Authors:  N C Phillips; M S Tsao
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Kupffer cells and liver metastasis. Optimization and limitation of activation of tumoricidal activity.

Authors:  N C Phillips
Journal:  Cancer Metastasis Rev       Date:  1989-12       Impact factor: 9.264

3.  Twenty-eighth annual meeting of the British Association for Cancer Research (in conjunction with the second annual meeting of the Association of Cancer Physicians). April 6-8, 1987, Newcastle-upon-Tyne, UK. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

4.  Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug.

Authors:  G Pratesi; G Savi; G Pezzoni; O Bellini; S Penco; S Tinelli; F Zunino
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.